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Introduction 
 
 Major depressive disorder (MDD) is an 
affective mood disorder with symptoms 
characterized by persistent and pervasive 
sadness, as well as low self-esteem and a loss of 
interest or pleasure in activities (Maughan, 
Collishaw, & Stringaris, 2013).  Due to the 
negative symptoms MDD produces, individuals 
suffering from this disease may encounter a 
reduction in marital functioning, timing and 
stability, parental functioning, education, 
employment status, and financial success 
(Kessler, 2012).  Also, MDD is commonly 
associated with many chronic physical disorders, 
such as arthritis, asthma, cancer, cardiovascular 
disease, diabetes, hypertension, as well as chronic 
respiratory disorders and pain conditions 
(Kessler, 2012).   
Out of all mental disorders MDD is the 
fourth leading cause for disability worldwide and 
is projected to be the second leading cause by 
2020 (Kessler, 2012).  Depression is a commonly 
occurring disorder with lifetime prevalence rates 
ranging from 1.5-19% (Kessler, 2012).  Many 
individuals that seek treatment for MDD often 
find the ailment to be chronically reoccurring 
(Kessler, 2012).   Within a year there is a one third 
to one half rate of reoccurrence for depressive 
episodes in lifetime cases (Kessler, 2012).   
The onset of many psychological 
disorders can appear at any time across ones 
lifespan (Wittchen, Nelson, & Lachner, 1998).  
As for MDD, its development can be seen more 
commonly in childhood and adolescence with a 
prevalence rate of 4-8% for adolescents and 2% 
in childhood (Hazell, 2009; Wittchen et al., 1998; 
Kessler, Avenevoli, & Merikangas, 2001; Nardi, 
Francesconi, Catena-Dell’osso, & Bellantuono, 
2013).  Many children and adolescents suffering 
from depression tend to have a stronger 
propensity for social withdrawal, substance 
abuse, and other mental disorders, as well as a 
decrease in school performance and social skills 
(Kessler et al., 2001; Nardi, Francesconi, Catena-
Dell’osso, & Bellantuono, 2013).  Within the 
pediatric population, there is a 40-90% rate of co-
morbidity with other conditions such as, 
dysthymia, autism spectrum disorders, ADHD, 
and substance abuse (Vogel, 2012).  Another 
complication that is of major concern is the 
increased risk of suicide within childhood and 
adolescent populations due to the effects of major 
depression (Vogel, 2012).  
Within this young and vulnerable 
population, it is possible that the diagnosis of 
childhood and adolescent depression may often 
remain unidentified, as a given depressive 
episode may not reach the diagnostic threshold 
for MDD (Nardi, Francesconi, Catena-Dell’osso, 
& Bellantuono, 2013).  The symptoms that linger 
from an undiagnosed case of MDD can 
potentially contain chronic clinical and social 
implications, as well as lead to a fully developed 
case of MDD for the depressed child (Nardi, 
Francesconi, Catena-Dell’osso, & Bellantuono, 
2013).  Clinical features of MDD symptoms in 
children and adolescents do not correlate directly 
with the symptoms exhibited by adult populations 
(Nardi, Francesconi, Catena-Dell’osso, & 
Bellantuono, 2013).    Symptoms in adolescent 
populations are duly expressed through somatic 
complaints, including irritability, loss of energy 
or fatigue, abdominal pain, and headaches (Nardi, 
Francesconi, Catena-Dell’osso, & Bellantuono, 
2013).    
In regards to treatment of MDD, there is 
a wide range of antidepressants that are 
efficacious for use in adult populations (Ryan, 
2005).  The first forms of psycho 
pharmacotherapy for depression were discovered 
in the 1960’s and are characterized as first 
generation antidepressants, known as monoamine 
oxidase inhibitors (MAOIs) and tricyclic 
antidepressants (TCAs) (Olver, Burrows, & 
Norman, 2001; Slattery, Hudson, & Nutt, 2004).  
Due to these compounds broad method of action 
by nonspecifically increasing monoamine levels 
in the synapse through reuptake inhibition or 
reduced metabolism, consequential side effects 
are expressed (Olver, Burrows, & Norman, 
2001).  As a result of these adverse side effects 
patient compliance with MAOIs and TCAs are 
generally low (Montgomery, 2006).  
Subsequently, a second generation of 
antidepressants known as selective serotonin 
reuptake inhibitors (SSRIs) was developed to 
improve on method of action and safety (Olver, 
Burrows, & Norman, 2001).  
As for childhood and adolescent 
populations, the options for treatment of MDD 
are far less (Gordon & Melvin, 2013; Ryan, 
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2005).  Specifically, in 2003 the FDA issued the 
SSRI fluoxetine as the only antidepressant that 
could safely be used within the pediatric 
population (Gordon et al., 2013; Masi, Liboni, & 
Brovedani, 2010).  Compared to adults, 
adolescents have different pharmacodynamics 
and pharmacokinetics (Gordon et al., 2013).  
Consequently, it appears that there is some 
evidence for age-dependent effects of SSRIs in 
humans and rodents (Olivier, Blom, Arentsen, & 
Homberg, 2011).  
Within the US the rate of suicide for 
adolescents is approximately seven for every 
100,000 individuals and most of those whom 
committed suicide were suffering from a mental 
disorder and half from MDD (Ryan, 2005).  
Attempted suicide rates for adolescents suffering 
from MDD are between 20-24% and rates of 
suicidal ideation are 15-66%.  Given the 
introduction of psychopharmaceutical 
interventions for MDD in the form of 
antidepressants, there appears to be a 
correlational decrease in rates of suicide for 
adolescents (Vogel, 2012).  Despite this 
correlation there has been an increase in suicidal 
ideation and attempts among adolescents who are 
taking these antidepressants (Vogel, 2012).  The 
risk ratio for suicide attempts and suicidal 
behavior or ideation as defined by the FDA for 
fluoxetine is 0-92 and for paroxetine 2-65 (Ryan, 
2005).  In regards to paroxetine, 
recommendations for prescribing the drug to 
depressed pediatric populations has been greatly 
cautioned due to paroxetine’s tendencies to 
increase the risk of deliberate self-harm or 
suicidal ideation (Soomro, 2008; Karanges et al., 
2011).  Fluoxetine on the other hand, has received 
adequate acceptance for treatment of MDD in the 
use of pediatric populations (Hazell, 2009; 
Gordon et al., 2013) 
The clinical efficacy of fluoxetine and 
paroxetines use in childhood and adolescence 
remains to be certain due to differences observed 
in associated risk of suicidal ideation or behavior 
and potential benefits from the SSRIs (Soomro, 
2008; Masi et al., 2010; Karanges et al., 2011).  
Perplexingly, these SSRIs are similar in both 
composition and method of action that is by 
blocking the serotonin transporter in the 
presynapse and thus increasing the amount of 
serotonin in the presynaptic membrane 
(Fitzgerald & Bronstein, 2013).  Consequently, 
the aim of the present research study is to further 
extend the knowledge on the age-dependent 
effects of chronic fluoxetine and paroxetine 
treatment in adolescent male and female rats, 
specifically in regards to anxiety and depression.   
Furthermore, we aspire to measure 
depression through the use of sucrose preference 
for anhedonia, meaning the inability to draw 
pleasure from previously joyful experiences.  
Also, in regards to measuring anxiety we will be 
using acoustic startle reflex, light/dark box, and 
elevated plus maze.  The aforementioned tests are 
valid measures of depression due to their 
manipulations that simulate states of depression 
through maternal separation, chronic mild stress 
or chronic dexamethasone treatment, dull sucrose 
preference, a reduction of time spent in the open 
arms of elevated plus maze, a reduction of time 
spent in the lit arena of the light/dark box, and a 
increase of prepulse inhibition and habituation in 
the acoustic startle response (Hill, Hellemans, 
Verma, Gorzalka, & Weinberg, 2012; Leussis, 
Freund, Brenhouse, Thompson, & Andersen, 
2012; Casarotto & Andreatini, 2007; Drapier et 
al., 2007; Quednow et al., 2006; Tsoory, Cohen, 
& Richter-Levin, 2007; Yacoubi, Rappeneau, 
Champion, Malleret, Vaugeois, 2006). 
Antidepressant treatment subsequently serves as 
a method to improve scores on these tests 
(Casarotto & Andreatini, 2007; Huot, 
Thrivikraman, Meaney, & Plotsky, 2001; Wang, 
Jiao, & Dulawa, 2011; Quednow et al., 2004).  
Due to the present lack of definitive evidence in 
the efficacy on the use of SSRIs in children under 
the age of 13 (Vogel, 2012), we aim to examine 
the SSRIs effects in this vulnerable population 
with rats starting on postnatal day (PD) 30.  As a 
result of the prevalence rates of adolescent MDD 
being twice as high for female humans than 
males, we chose to investigate the effects of these 
SSRIs on both sexes (Vogel, 2012; Frackiewicz, 
Sarmek, & Cutler, 2000; Scheibe, Preuschhof, 
Cristi, & Bagby, 2003).   
 
Materials and Methods 
 
Subjects  
A total of ___ male and female rats of Sprague-
Dawley descent (Charles River Laboratories, 
Wilmington, MA), born and raised at California 
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State University, San Bernardino (CSUSB) were 
used.  Litters were culled on PD 3 to a maximum 
of 10 rat pups.  Pups were housed with the dam 
until PD 20.  After weaning, rats were housed in 
group cages with same-sex litter mates (4-6 rats 
per cage).  After the sucrose preference test (PD 
60), rats were single housed for the remainder of 
the behavioral experiments.  A temperature of 22-
24°C and a 12-hr light/dark cycle was held inside 
the colony room.  All animals were treated 
according to the “Guide for the Care and Use of 
Mammals in Neuroscience and Behavioral 
Research” (National research Council, 2010) 
under a research protocol approved by the 
Institutional Animal Care and Use Committee 
and CSUSB.   
 
Drugs  
Fluoxetine hydrochloride and paroxetine 
hydrochloride was obtained from Toronto 
Research Chemicals (Toronto, Canada).  Both 
fluoxetine and paroxetine was dissolved in a 50% 
dimethyl sulfoxide (DMSO)/water solution and 
injected intraperitoneally (IP) at a volume of _ 
ml/kg. 
 
Apparatus 
EPM 
The EPM was constructed out of black plastic and 
was stationed 50 cm above floor level (San Diego 
Instruments, San Diego).  The EPM contained 
four perpendicularly aligned arms, each of which 
was 50 cm long and 10 cm wide.  The two 
enclosed arms contained 30 cm high walls, while 
the two open arms were exposed with a .9 cm lip 
for the prevention of rats falling of the EPM.  The 
EPM was stationed in the center of a quiet, dimly 
lit room, with a digital video camera located 
directly above the maze. 
 
Acoustic startle response 
The acoustic startle reflex will be measured with 
the Coulbourn Animal Acoustic Startle System 
(Coulbourn Instruments, Whitehall, PA), which 
contains weight sensitive platforms inside 
individual sound-attenuating chambers.  
Ventilation fans built into the chambers produced 
the background noise.  Rats were placed in a 
small, ventilated holding cage, which restricted 
extensive locomotion.   
 
Light-dark box 
The light-dark box contained a 41 x 41 cm base 
with photobeam receptors (Coulbourn 
Instruments, Whitehall, PA).  The walls of the 
chambers were 41 cm high.  The dark 
compartment was composed of a dark plastic box 
covering half of the base.  The plastic box also 
had a small transition door between the light and 
dark compartments.     
 
Procedures 
Sucrose preference 
Rats (N=10-11) began sucrose preference 
training on PD 26 with a two-bottle choice test.  
On day one of training, rats were individually 
housed and habituated to drinking water from two 
bottles.  For the next three days (PD 27-30), one 
of the two bottles contained either a .5 or 2% 
sucrose solution.  On each of the three days, the 
bottles were weighed and refilled at the same time 
every morning.  To avoid position preferences, 
the bottles were systematically switched to either 
the left or right each day.  On the last day of 
sucrose training, (PD 29) rats were group housed 
with same-sex littermates.  On the following day, 
rats were treated with paroxetine (2.5 or 10 
mg/kg), fluoxetine (10 mg/kg), or vehicle once 
daily from PD 30 to PD 59.  Following the last 
injection, rats were individually housed and given 
a final sucrose preference test beginning on PD 
59 and ending on PD 60.  Sucrose preference was 
defined using the following formula: [(weight of 
sucrose ingested) / (weight of water ingested + 
weight of sucrose ingested) x 100].  Assessment 
of change in sucrose preference due to SSRI 
treatment was accomplished by calculating 
difference scores (i.e., the average of the three 
baseline scores minus the final difference score).  
 
Elevated plus maze 
After the cessation of the sucrose preference test 
on PD 60, rats designated for EPM testing were 
individually brought to another quite testing 
room.  Each rat was placed in the middle of the 
EPM with the head facing the open arm.  Rats 
were allowed to roam freely on the EPM for 
approximately 5-min.  Recordings of the rat’s 
activity on the EPM (time spent in the center and 
open or closed arms) was documented via a video 
camera and scored afterwards.  Data entries for 
the open or closed arms were documented when 
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all four paws crossed the thresholds.  Data entry 
for the center of the EPM was documented when 
two paws crossed the threshold. 
 
Light-dark box 
Following the cessation of the sucrose preference 
test on PD 60, rats designated for light-dark box 
testing were brought (two at a time) to a quite 
separate testing room.  Each rat was individually 
placed into the front right corner of the light-dark 
box and given 10-min to roam freely.  Data was 
recorded for time spent in each of the light and 
dark compartments, as well as the frequency of 
transitions into the light compartment, and beam 
interruptions in the light and dark compartments.  
 
Acoustic startle reflex/prepulse inhibition 
After the cessation of the sucrose preference test 
on PD 60, rats designated for acoustic startle 
reflex/prepulse inhibition were brought (two at a 
time) to a quite separate testing room and were 
placed into a testing chamber for a 5-min 
acclimation period prior to the delivery of any 
stimulus.  Each session was conducted using a 70 
dB white background noise.  On the first and last 
six trails of the session, a startling stimulus (50 
dB above the background (or 120 dB), 40 ms) 
was presented alone.  The remaining trails were 
presented in a pseudorandom order and included 
12 trails (middle trails) with the startling stimulus 
alone (used to calculate % PPI and average startle 
amplitude), and 12 trails/prepulse stimulus 
intensity on which a prepulse stimulus (20 ms) 
preceded the startling stimulus by 100 ms.  The 
prepulse stimuli were 3, 6, 12, 15, or 18 dB above 
the background.  Additionally, there were 8 trails 
on which no stimulus was presented, but activity 
within the chamber was monitored.  The inter-
trail inter will be 20 s.  Startle amplitude on the 
12 middle trails during which the startle stimulus 
alone was presented was averaged.  These data 
were used in the analyses of baseline startle 
amplitude.  Percent prepulse inhibition was 
calculated as [100 x (average startle amplitude on 
the prepulse trails/average startle amplitude on 
the middle startle stimulus alone trials)].  Percent 
habituation will be calculated as [100 x average 
startle amplitude on the last 6 startle alone 
trails/average startle amplitude on the first 6 
startle alone trails)]. 
 
Expected Results 
 
In regards to body weight, we expect that 
adolescent rats treated with fluoxetine and 
paroxetine to have less weight gain than rats 
treated with vehicle (Homberg et al., 2011; 
Iñiguez, Warren, & Bolaños-Guzmán, 2010; de 
Jong et al.,).  Specifically, we plan to analyze data 
from body weights obtained during injections 
with a 3 x 2 x 30 (pretreatment condition x sex x 
day) repeated measures ANOVA.  Measurement 
of anhedonia will be achieved through the use of 
sucrose preference test, in which we expect 
adolescent rats treated with fluoxetine and 
paroxetine to show less sucrose consumption and 
preference than rats treated with vehicle (Iñiguez, 
Warren, & Bolaños-Guzmán, 2010).  
Furthermore, we plan to analyze data from the 
sucrose preference test with a 3 x 2 x 2 
(pretreatment x sex x sucrose solution) repeated 
measures ANOVA.  For measurement of anxiety-
like behaviors we will be using the elevated plus 
maze (EPM), in which we expect adolescent rats 
treated with fluoxetine and paroxetine to spend 
less time in the open arms of the EPM than rats 
treated with vehicle (Homberg et al., 2011; 
Vorhees, Morford, Graham, Skelton, & Williams, 
2011; Oh, Zupan, Gross, & Toth, 2009; Iñiguez, 
Warren, & Bolaños-Guzmán, 2010; Drapier et 
al., 2007; de Jong et al., 2006).  Moreover, we 
plan to analyze data from the EPM with a 3 x 2 
(pretreatment x sex) ANOVA.  As for acoustic 
startle response, we expect adolescent rats treated 
with fluoxetine and paroxetine to exhibit a 
consistent startle response where rats treated with 
vehicle would show a decrease in startle response 
(Homberg et al., 2011; Vorhees; de Jong et al., 
2006).  In regards to the light/dark box, we expect 
adolescent rats treated with fluoxetine and 
paroxetine to stay in the dark compartment for a 
longer period of time and take longer to emerge 
into the light compartment when compared to rats 
treated with vehicle (Arrant, Coburn, Jacobsen, & 
Kuhn, 2013).  Additionally, we plan to analyze 
data from the light/dark box with a 3 x 2 
(pretreatment x sex) ANOVA. 
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